Sign in

SLGL on Nasdaq

Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd. is a pharmaceutical preparations company, listed on Nasdaq (SLGL).1

Price unavailable

Last updated Oct 21, 2026.

Overview

$19.4MRevenue, fiscal 20252
-$6.1MNet income, fiscal 20252

Compare with Evofem Biosciences, Inc., SCYNEXIS INC or CASI Pharmaceuticals, Inc., or pick any stock.

  • TickerSLGL on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersL31
  • Incorporated inIsrael3
  • Business address7 Golda Meir St., Weizmann Science Park, Ness Ziona, 74036483
  • Filer categoryNon-accelerated filer3

See how the biggest companies compare on our leaderboards

2024 and 2025 were approximately $134, $2 and $47, respectively. Our current capital expenditure involves equipment and leasehold improvements.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-38.9%Operating margin2
-31.6%Net margin2
68.0%Revenue growth, 20252
-26.9%Return on equity2
$275.0KFree cash flow2

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

License brought in 96% of the revenue Sol-Gel Technologies Ltd. broke down this way in fiscal 2025.

  1. License$18.6M296%up 90% from 2024
  2. Royalty$707.0K24%down 56% from 2024
  3. Service, Other$82.0K20%down 35% from 2024
Products and services by year
Products and services202320242025
License$380.0K$9.8M$18.6M
Royalty$1.2M$1.6M$707.0K
Service, Other$0$126.0K$82.0K

Regions

United States brought in 86% of the revenue Sol-Gel Technologies Ltd. broke down this way in fiscal 2025.

  1. United States$16.7M286%
  2. CA [member]$1.7M29%up 146% from 2024
  3. Switzerland$711.0K24%down 52% from 2024
  4. Segment Geographical Groups Of Countries Group Five$278.0K21%down 60% from 2024
  5. [Canada]$27.0K20%down 99% from 2024
Regions by year
Regions202320242025
United States$0$0$16.7M
CA [member]$380.0K$681.0K$1.7M
Switzerland$1.0M$1.5M$711.0K
Segment Geographical Groups Of Countries Group Five$147.0K$691.0K$278.0K
[Canada]$0$4.9M$27.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$22.8M

Out of $19.4M in revenue.2 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending15¢$47.0K
  • Kept or used elsewhere85¢$275.0K

Out of $322.0K of cash from operations.2

Financial statements

Revenue567892$19.4M in 2025+14929% since 2018
0$10.0M$20.0M$30.0M$40.0M2018: $129.0K$129.0K20182019: $22.9M$22.9M2019+17655%2020: $8.8M$8.8M2020−62%2021: $31.3M$31.3M2021+257%2022: $3.9M$3.9M2022−88%2023: $1.6M$1.6M2023−60%2024: $11.5M$11.5M2024+642%2025: $19.4M$19.4M2025+68%
Operating income567892-$7.5M in 2025−78% since 2018
-$40.0M-$30.0M-$20.0M-$10.0M0$10.0M2018: -$33.5M-$33.5M20182019: -$25.9M-$25.9M2019−23%2020: -$30.2M-$30.2M2020+17%2021: $3.0M$3.0M20212022: -$16.2M-$16.2M20222023: -$29.3M-$29.3M2023+80%2024: -$12.0M-$12.0M2024−59%2025: -$7.5M-$7.5M2025−37%
Net income567892-$6.1M in 2025−81% since 2018
-$40.0M-$30.0M-$20.0M-$10.0M0$10.0M2018: -$32.2M-$32.2M20182019: -$24.6M-$24.6M2019−24%2020: -$29.3M-$29.3M2020+19%2021: $3.2M$3.2M20212022: -$14.9M-$14.9M20222023: -$27.2M-$27.2M2023+83%2024: -$10.6M-$10.6M2024−61%2025: -$6.1M-$6.1M2025−42%

Every line of the income statement as filed: the last 3 fiscal years, latest first.2

Period ending2025-12-312024-12-312023-12-31
REVENUES$19.4M$11.5M$1.6M
Research and development expenses$22.8M$17.8M$23.5M
GENERAL AND ADMINISTRATIVE EXPENSES$4.2M$5.7M$7.4M
OTHER INCOME, net$54.0K$0$55.0K
TOTAL OPERATING LOSS-$7.5M-$12.0M-$29.3M
FINANCIAL INCOME, net$1.4M$1.4M$2.1M
NET LOSS FOR THE YEAR-$6.1M-$10.6M-$27.2M
BASIC LOSS PER ORDINARY SHARE-$2.19-$3.79-$10.01
DILUTED LOSS PER ORDINARY SHARE-$2.19-$3.79-$10.01
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE2.8M shares2.8M shares2.7M shares
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE2.8M shares2.8M shares2.7M shares

Compare Sol-Gel Technologies Ltd. with another company

Corporate structure

Sol-Gel Technologies Ltd. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Sol-Gel Technologies Ltd.

  • Sol-Gel Technologies Ltd. L3

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Sol-Gel Technologies Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$4.4M2 Dec 31, 2025$6.2M2 Dec 31, 2024−29.1%
Accumulated depreciation$4.3M2 Dec 31, 2025$6.0M2 Dec 31, 2024−29.1%
Property and equipment, net$140.0K2 Dec 31, 2025$202.0K2 Dec 31, 2024−30.7%
Operating-lease assets (leased space)$1.0M2 Dec 31, 2025$1.4M2 Dec 31, 2024−28.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$11.0M2 Dec 31, 2025$19.5M2 Dec 31, 2024−43.4%
Marketable securities, current$13.0M2 Dec 31, 2025$4.4M2 Dec 31, 2024+193.0%

Leadership

Who has led Sol-Gel Technologies Ltd., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Moshe Arkin2026–now

Chair

  1. Moshe Arkin2026–now

Chief financial officer

  1. Eyal Ben-Or2026–now

Chief operating officer

  1. Itzik Yosef2026–now
Board members and other officers (8)

Timeline

  1. Mar 18, 2026New chief executive Moshe Arkin becomes CEO11

Calendar

Coming up

  1. Nov 19, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($2.13) a share, on Nov 20, 2025.22

Drug trials and FDA: recently

  1. Aug 20, 2026Phase 3 trial completed Phase 3 trial of Patidegib Topical Gel and Patidegib Topical Gel with no active patidegib in Gorlin Syndrome: primary completion Aug 20, 2026, no results posted yet (ClinicalTrials.gov NCT06050122).23

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

185 filings to the SEC since October 2021: 6 annual reports, 37 insider forms, 23 large holders, 119 other. The latest 20:

  1. Oct 6, 20266-K EDGAR
  2. Sep 30, 20266-K EDGAR
  3. Sep 17, 20266-K EDGAR
  4. Sep 14, 20264 EDGAR
  5. Sep 9, 20264 EDGAR
  6. Sep 3, 20264 EDGAR
  7. Aug 31, 20264 EDGAR
  8. Aug 20, 20266-K EDGAR
  9. Aug 14, 20264 EDGAR
  10. Jul 15, 20264 EDGAR
  11. Jul 10, 20264 EDGAR
  12. Jul 2, 20264 EDGAR
  13. Jun 9, 2026SCHEDULE 13G/A EDGAR
  14. May 28, 20266-K EDGAR
  15. May 22, 20264 EDGAR
  16. May 14, 20264 EDGAR
  17. May 6, 2026SCHEDULE 13G/A EDGAR
  18. Apr 15, 2026SCHEDULE 13D/A EDGAR
  19. Mar 31, 2026SCHEDULE 13G EDGAR
  20. Mar 24, 20264 EDGAR

The 185 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

43 open-market trades by officers, directors and large owners since October 2021: 43 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 11, 2026Opaleye Management Inc.10% ownerBuy1,493$65.95$98.5KForm 4
Sep 10, 2026Opaleye Management Inc.10% ownerBuy1,631$66.80$109.0KForm 4
Sep 9, 2026Opaleye Management Inc.10% ownerBuy3,097$68.71$212.8KForm 4
Sep 8, 2026Opaleye Management Inc.10% ownerBuy3,861$68.82$265.7KForm 4
Sep 4, 2026Opaleye Management Inc.10% ownerBuy3,018$69.14$208.7KForm 4
Sep 2, 2026Opaleye Management Inc.10% ownerBuy900$68.95$62.1KForm 4
Sep 1, 2026Opaleye Management Inc.10% ownerBuy783$69.52$54.4KForm 4
Aug 31, 2026Opaleye Management Inc.10% ownerBuy5,217$68.28$356.2KForm 4
Aug 28, 2026Opaleye Management Inc.10% ownerBuy35,113$69.32$2.4MForm 4
Aug 12, 2026Opaleye Management Inc.10% ownerBuy951$71.50$68.0KForm 4
Jul 14, 2026Opaleye Management Inc.10% ownerBuy920$73.43$67.6KForm 4
Jul 13, 2026Opaleye Management Inc.10% ownerBuy775$73.89$57.3KForm 4
Jul 10, 2026Opaleye Management Inc.10% ownerBuy229$73.95$16.9KForm 4
Jul 8, 2026Opaleye Management Inc.10% ownerBuy300$73.69$22.1KForm 4
Jul 2, 2026Opaleye Management Inc.10% ownerBuy1,400$71.97$100.8KForm 4
Jul 1, 2026Opaleye Management Inc.10% ownerBuy312$71.99$22.5KForm 4
May 20, 2026Opaleye Management Inc.10% ownerBuy1,563$64.43$100.7KForm 4
May 13, 2026Opaleye Management Inc.10% ownerBuy1,937$66.87$129.5KForm 4
May 12, 2026Opaleye Management Inc.10% ownerBuy1,500$67.98$102.0KForm 4
Mar 24, 2026Opaleye Management Inc.10% ownerBuy39,665$72.00$2.9MForm 4

All 43 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Sol-Gel Technologies Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSol-Gel Technologies Ltd.1
  • CIK0001684693
  • Filer statusNon- accelerated filer not an emerging growth company; not a shell company4
  • Incorporated inIsrael4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address7 Golda Meir St., Weizmann Science Park, Ness Ziona, L3 7403648, Israel1
  • Phone972893134331
  • Shares outstanding2,786,158 shares as of Dec 31, 20254
  • AuditorKesselman & Kesselman, Tel-Aviv, Israel PCAOB ID 1309; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceSep 28, 20161
  • Filings328 in all: 6-K (160), 4 (24), 3 (12), 144 (10), CORRESP (10), UPLOAD (10), 20-F (9), 424B3 (9)1
    All 34 form types

    EFFECT (9), SC 13G/A (9), 424B5 (7), 6-K/A (6), F-1/A (5), SC 13G (5), SCHEDULE 13G/A (5), POS AM (4), SC 13D/A (4), SCHEDULE 13G (4), DRS/A (3), F-3 (3), S-8 (3), SCHEDULE 13D/A (3), DRSLTR (2), F-1 (2), 20-F/A (1), 4/A (1), 424B4 (1), 8-A12B (1), CERT (1), CT ORDER (1), DRS (1), F-3/A (1), FWP (1), SC 13D (1)

  • Latest filingsAnnual report (20-F) Mar 19, 2026

Securities registered for trading

ClassSymbolExchange
Ordinary SharesSLGLThe Nasdaq Stock Market LLC

From the cover page of the 20-F filed Mar 19, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29